Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention.
作者信息
Williams Arthur Robin, Mauro Christine M, Feng Tianshu, Wilson Amanda, Cruz Angelo, Olfson Mark, Crystal Stephen, Samples Hillary, Chiodo Lisa
机构信息
Department of Psychiatry, New York State Psychiatric Institute, Columbia University Medical Center (Williams, Olfson); Columbia University Mailman School of Public Health (Mauro, Olfson); Research Foundation for Mental Hygiene, New York (Feng); Addiction Research and Education Foundation, Florence, Mass. (Wilson, Cruz); North-Star Care, Inc. Gig Harbor, Wash. (Wilson); Institute for Health, Health Care Policy, and Aging Research, Rutgers University, New Brunswick, N.J. (Crystal, Samples); University of Massachusetts Amherst, School of Nursing, Amherst, Mass. (Chiodo).
出版信息
Am J Psychiatry. 2023 Jun 1;180(6):454-457. doi: 10.1176/appi.ajp.20220456. Epub 2022 Oct 26.
Abstract
摘要
相似文献
1
Performance Measurement for Opioid Use Disorder Medication Treatment and Care Retention.
Am J Psychiatry. 2023 Jun 1;180(6):454-457. doi: 10.1176/appi.ajp.20220456. Epub 2022 Oct 26.
2
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
Addict Behav. 2022 Jan;124:107113. doi: 10.1016/j.addbeh.2021.107113. Epub 2021 Sep 6.
3
Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.
J Subst Abuse Treat. 2015 May;52:40-7. doi: 10.1016/j.jsat.2014.12.002. Epub 2014 Dec 22.
4
Opioid agonist treatment for pharmaceutical opioid dependent people.
Cochrane Database Syst Rev. 2016 May 9(5):CD011117. doi: 10.1002/14651858.CD011117.pub2.
5
Limited acceptance of buprenorphine in recovery residences in South Florida: A secret shopper survey.
J Subst Use Addict Treat. 2025 Jan;168:209535. doi: 10.1016/j.josat.2024.209535. Epub 2024 Oct 5.
6
Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.
Addiction. 2014 Jan;109(1):20-32. doi: 10.1111/add.12303. Epub 2013 Aug 15.
7
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.
JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702.
8
Health Services Usage in Patients Receiving Buprenorphine for Opioid Use Disorder or Long-Term Opioid Therapy for Chronic Pain: Retrospective Cohort Study.
JMIR Form Res. 2025 Jun 19;9:e66596. doi: 10.2196/66596.
9
10-year retention of a comprehensive treatment model of buprenorphine for opioid use disorder.
J Addict Dis. 2025 Jan-Mar;43(1):44-51. doi: 10.1080/10550887.2024.2315366. Epub 2024 Feb 24.
10
Effectiveness of methadone versus buprenorphine in the treatment of opioid use disorder: secondary analyses of prospective cohort study data.
BMJ Open. 2025 Jun 17;15(6):e095645. doi: 10.1136/bmjopen-2024-095645.
引用本文的文献
1
Integrating HIV prevention services into care settings for people with opioid use disorder (OUD): a study protocol for implementation strategy development and modeling.
Implement Sci Commun. 2025 Sep 1;6(1):93. doi: 10.1186/s43058-025-00782-1.
2
Are Treatment Services Ready for the Use of Big Data Analytics and AI in Managing Opioid Use Disorder?
J Med Internet Res. 2025 Apr 28;27:e58723. doi: 10.2196/58723.
3
Advancing Health Equity Through Substance Use Medical Record Data Sharing: Insights from Healthcare Providers.
Int J Environ Res Public Health. 2025 Mar 21;22(4):462. doi: 10.3390/ijerph22040462.
4
Development and validation of a pragmatic measure of context at the organizational level: The Inventory of Factors Affecting Successful Implementation and Sustainment (IFASIS).
Implement Sci Commun. 2025 Apr 25;6(1):50. doi: 10.1186/s43058-025-00726-9.
5
State sequence analysis of daily methadone dispensing trajectories among individuals at United States opioid treatment programs before and following COVID-19 onset.
Addiction. 2025 Jun;120(6):1207-1222. doi: 10.1111/add.70008. Epub 2025 Feb 26.
6
Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder.
Addict Sci Clin Pract. 2024 Dec 2;19(1):91. doi: 10.1186/s13722-024-00510-5.
7
Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings.
BMC Prim Care. 2024 Oct 11;25(1):361. doi: 10.1186/s12875-024-02609-9.
8
Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.
J Subst Use Addict Treat. 2024 Dec;167:209511. doi: 10.1016/j.josat.2024.209511. Epub 2024 Sep 5.
9
Outpatient-Based Opioid Treatment Engagement and Attendance: A Prospective Cohort Study of Homeless-Experienced Adults.
J Gen Intern Med. 2024 Nov;39(15):2927-2934. doi: 10.1007/s11606-024-08916-2. Epub 2024 Jul 10.
10
US payment policy for medications to treat opioid use disorder: landscape and opportunities.
Health Aff Sch. 2024 Feb 27;2(3):qxae024. doi: 10.1093/haschl/qxae024. eCollection 2024 Mar.
本文引用的文献
1
Non-prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder.
J Subst Abuse Treat. 2022 Aug;139:108770. doi: 10.1016/j.jsat.2022.108770. Epub 2022 Mar 21.
2
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.
JAMA Psychiatry. 2021 Sep 1;78(9):979-993. doi: 10.1001/jamapsychiatry.2021.0976.
3
Transforming Mental Health And Addiction Services.
Health Aff (Millwood). 2021 Feb;40(2):226-234. doi: 10.1377/hlthaff.2020.01472. Epub 2021 Jan 21.
4
Impact Of Long-Term Buprenorphine Treatment On Adverse Health Care Outcomes In Medicaid.
Health Aff (Millwood). 2020 May;39(5):747-755. doi: 10.1377/hlthaff.2019.01085.
5
Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services.
Addiction. 2020 Sep;115(9):1683-1694. doi: 10.1111/add.14991. Epub 2020 Feb 24.
6
Trends in Buprenorphine Treatment in the United States, 2009-2018.
JAMA. 2020 Jan 21;323(3):276-277. doi: 10.1001/jama.2019.18913.
7
Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.
Am J Psychiatry. 2020 Feb 1;177(2):117-124. doi: 10.1176/appi.ajp.2019.19060612. Epub 2019 Dec 2.
8
Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?
J Subst Abuse Treat. 2019 Oct;105:37-43. doi: 10.1016/j.jsat.2019.07.010. Epub 2019 Jul 24.
9
Development of a Cascade of Care for responding to the opioid epidemic.
Am J Drug Alcohol Abuse. 2019;45(1):1-10. doi: 10.1080/00952990.2018.1546862. Epub 2019 Jan 24.
10
Promoting opioid overdose prevention and recovery: An exploratory study of an innovative intervention model to address opioid abuse.
Int J Drug Policy. 2019 Feb;64:21-29. doi: 10.1016/j.drugpo.2018.12.004. Epub 2018 Dec 12.
Zotero 插件